A delayed filing by Alexion Pharmaceuticals threatens to worsen a rare disease biotech company’s rough year.
from WSJ.com: Markets http://www.wsj.com/articles/biotech-company-bloodied-by-sales-investigation-1478795929?mod=rss_markets_main
via https://ifttt.com/ IFTTT
No comments:
Post a Comment